

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

SMITH KLINE & FRENCH)
LABORATORIES LIMITED and)
SMITHKLINE BEECHAM)
CORPORATION d/b/a)
GLAXOSMITHKLINE,)
)
Plaintiffs,)
v.)
)
TEVA PHARMACEUTICALS USA, INC.,)
)
Defendant.)
_____)

Civil Action No. 05-197-GMS

LIST OF ADMITTED EXHIBITS

Patricia Smink Rogowski (Del. ID No. 2632)
CONNOLLY BOVE LODGE & HUTZ LLP
The Nemours Building
1007 North Orange Street
Wilmington, DE 19801
Phone: (302) 658-9141
Fax : (302) 658-5614
Attorney for Plaintiffs

William F. Lee, Esq.
WILMER, CUTLER, PICKERING,
HALE AND DORR LLP
60 State Street
Boston, MA 02109
Phone: (617) 526-6000
Fax: (617) 526-5000

William G. McElwain, Esq.
Henry N. Wixon, Esq.
Amy K. Wigmore, Esq.
Michael Gordon, Esq.
Mark Rienzi, Esq.
WILMER, CUTLER, PICKERING,
HALE AND DORR LLP
1875 Pennsylvania Avenue, NW
Washington, D.C. 20006
Phone: (202) 942-8400
Fax: (202) 942-8484

Dated: February 7, 2007

GSK v. TEVA
LIST OF ADMITTED EXHIBITS

Exhibit Number	Description	Method of Admission
DTX 19	'860 Patent Public Prosecution History	Stipulated
DTX 20	'808 Patent Public Prosecution History	Stipulated
DTX 22	DX-22, Eden R., Curriculum Vitae	Stipulated
DTX 23	DX-23, SK&F Project Meeting Minutes March 13, 1986	Stipulated
DTX 24	Laboratory Notebook No. 3293/55573	Stipulated
DTX 25	DX-25, SK&F Project Meeting Minutes February 27, 1987	Stipulated
DTX 26	DX-26, R. Eden et al., <i>Preclinical Pharmacology of Ropinirole(SK&F 101468-A) a Novel Dopamine D2 Agonist</i> , 1991	Stipulated
DTX 28	DX-28, Draft Project Plan, August 1987	Stipulated
DTX 33	DX-33, Costall, B., Curriculum Vitae	Stipulated
DTX 37	CX-37, Costall, B. and R.J. Naylor, Action of SK&F 101468-A in a Model of Parkinson's Disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the common marmoset, September 1987	Stipulated
DTX 39	DX-39, Preclinical Profile of SK&F 101468-A (Ropinirole)	Stipulated
DTX 40	Cannon JG. <i>The Design of Potential Anti-Parkinsonian Drugs: What is the Dopaminergic Pharmacophore in Ergot Alkaloids?</i> Proc. Iowa Acad Sci 1986; 93:169-174.	Stipulated
DTX 41	DX-41, Teva's Notice of 30(b)(6) Deposition April 5, 2006	Stipulated
DTX 42	DX-42, Gallagher, G., U.S. Patent 4,452,808, June 5, 1984	Stipulated
DTX 45	DX-45, Gallagher, G., Laboratory Notebook	Stipulated
DTX 46	DX-46, Gallagher, G., Notebook	Stipulated
DTX 49	DX-49, Hieble, J.P. memo to R. Eden re <i>Potential Back-Up Compounds for SK&F 101468 as Anti-Parkinson's Drugs</i>	Stipulated
DTX 50	DX-50, Hieble, J.P. memo to R. Eden re <i>Potential Back-Up Compounds for SK&F 101468 as Anti-Parkinson's Drugs</i>	Stipulated
DTX 56	Syntheses and in Vitro Evaluation of 4-(2-Aminoethyl)-2(3H)-indolones and Related Compounds as Peripheral Prejunctional Dopamine Receptor Agonists by DeMarinis, et al	Admitted 12/18/2006 (Long Direct)
DTX 62	DX-62, J. Cannon et al: <i>Proposed Dopaminergic Pharmacophore of Lergotile, Pergolide, and Related Ergot Alkaloid Derivatives</i> , J. Med. Chem. 24:238-240 (1981)	Admitted 12/18/2006 (Long Direct)
DTX 64	DX-64, Huffman, W. et al., <i>Communications to the Editor re 4-(Aminoalkyl)-7-hydroxy-2(3H)-indolones, a Novel Class of Potent Presynaptic Dopamine Receptor Agonists</i> , J. Med., Chem., July 1983	Stipulated
DTX 71	DX-71, Department of Drug Metabolism and Pharmacokinetics: <i>Preliminary Investigation into the C.N.S. Penetration of SK&F 101468 and Related Material in the Conscious Rat</i> . March 1986	Stipulated
DTX 72	DX-72, SK&F Project Meeting Minutes, February 10, 1986	Stipulated
DTX 74	DX-74, SK&F Project Meeting Minutes, May 20, 1986	Stipulated
DTX 76	DX-76, SK&F Project Meeting Minutes, October 30, 1986	Stipulated
DTX 77	DX-77, SK&F Project Meeting Minutes, December 11, 1986	Stipulated
DTX 78	DX-78, SK&F Project Meeting Minutes, February 18, 1987	Stipulated
DTX 86	DX-86, SK&F Project Review Panel memo to SK&F 101468 Project Team re <i>Critique of SK&F 101468</i> , October 12, 1987	Stipulated
DTX 89	DX-89, SK&F Project Meeting Minutes, March 3, 1988	Stipulated

Exhibit Number	Description	Method of Admission
DTX 92	DX-92, SK&F 101468 <i>Worldwide Development Plan and Review Document</i> , September 1987	Stipulated
DTX 96	DX-96, Wixon, H. email to D. Owen re GSK Retention Confirmation	Stipulated
DTX 97	DX-97, Owen, D., Declaration and Power of Attorney, May 19, 1988	Stipulated
DTX 98	DX-98, SK&F Project Meeting Minutes, May 29, 1986	Stipulated
DTX 99	DX-99, SK&F Project Meeting Minutes, September 28, 1988	Stipulated
DTX 100	DX-100, SK&F Project Meeting Minutes, October 30, 1986	Stipulated
DTX 101	DX-101, SK&F Project Meeting Minutes, July 16, 1986	Stipulated
DTX 102	DX-102, SK&F Project Meeting Minutes September 3, 1986	Stipulated
DTX 133	DX-133, Giddings, P.J., letter to European Patent Office, November 25, 1991	Stipulated
DTX 134	DX-134, European Patent Office letter to P.J. Giddings, July 26, 1991	Stipulated
DTX 140	Plaintiff GSK's Responses to Defendant's 1 st Set of Interrogatories, October 3, 2005	Stipulated
DTX 141	Plaintiff GSK's Supplemental Responses to Defendant's 1 st Set of Interrogatories, April 10, 2006	Stipulated
DTX 142	Plaintiff GSK's 2 nd Supplemental Responses to Defendant's 1 st Set of Interrogatories, June 29, 2006	Stipulated
DTX 160	Cannon JG, Hsu FL, Long JP, Flynn JR, Costall B, Naylor RJ. <i>Preparation and biological actions of some symmetrically N,N-disubstituted dopamines</i> . J Med Chem 1978; 21(3):248-253.	Admitted 12/18/2006 (Long Direct)
DTX 172	TEV-RQEXP000217-220, Steinsland, O. and Hieble, J.P., <i>Dopaminergic Inhibition of Andrenergic Neurotransmission as a Model for Studies on Dopamine Receptor Mechanisms</i> , Science, 1978, Vol. 199:443-445	Admitted 12/18/2006 (Long Direct)
DTX 179	TEV-RQEXP000249-254, Cannon, J.G., <i>The Design of Potential Anti-Parkinsonian Drugs: What is the Dopaminergic Pharmacophore in Ergot Alkaloids?</i> Proc. Iowa Acad. Sci, 1986, Vol. 93, No. 4: 169-174	Admitted 12/18/2006 (Long Direct)
DTX 220	GSK-SUD000065-86, Mirapex Tablets -- Information Booklet	Admitted 12/18/2006 (Tarsy Direct)
DTX 221	GSK-SUD000126-162, Requip Tablets -- Prescribing Information	Admitted 12/18/2006 (Tarsy Direct)
DTX 312	GSK-REQ 094434-94657, Internal File History for U.S. Patent No. 4,824,860	Stipulated
DTX 355	Curriculum Vitae, H.C. Boghigian	Stipulated
DTX 356	Curriculum Vitae, J.G. Cannon	Stipulated
DTX 357	Curriculum Vitae, Long, J.P	Admitted 12/18/2006 (Long Direct)
DTX 358	Curriculum Vitae, Tarsy, D.	Admitted 12/18/2006 (Tarsy Direct)
DTX 361*	Expert Report of Harry Bohigian	Stipulated
DTX 375	DX 171, Holden, K., United States Patent 4,206,210, June 3, 1980	Admitted 12/20/2006 (Jenner Cross)
DTX 376	DX 172, Hieble, P. et al., <i>Synthesis and Evaluation of Non-Catechol D-1 and D-2 Dopamine Receptor Agonists: Benzimidazol-2-one, Benzoxazol-2-one, and the Highly Potent Benzothiazol-2-one 7-Ethylamines</i> , J. Med. Chem., 1987	Admitted 12/19/2006 (Bartlett Cross)
DTX 377	DX 173, Kaiser, C. and T. Jain, <i>Dopamine Receptors: Functions, Subtypes and Emerging Concepts</i> , Medicinal Research Reviews, Vol. 5, No. 2, 145-229, 1985	Admitted 12/20/2006 (Jenner Cross)
DTX 383	Plaintiff GSK's Third Supplemental Responses to Defendants 1 st Set of Interrogatories, August 16, 2006	Stipulated

Exhibit Number	Description	Method of Admission
DTX 391	PX 64, Daniel Tarsy, M.D., Initial Treatment of Parkinson's Disease, Current Treatment Options in Neurology 2006. 8:224-235	Admitted 12/18/2006 (Tarsy Direct)
PTX 13	U.S. Patent No. 4,452,808	Admitted 12/18/2006 (Long Direct)
PTX 17	Journal of Medicinal Chemistry article 4-[2-(Di-n-propylamino)ethyl]-2(3H)-indolone: A Prejunctional Dopamine Receptor Agonist.	Admitted 12/18/2006 (Long Direct)
PTX 35	U.S. Patent No. 4,824,860	Admitted 12/18/2006 (Long Direct)
PTX 36	U.S. Patent No. 4,314,944	Stipulated
PTX 53	Patent Certification (From Teva's ANDA)	Admitted 12/18/2006 (Jaskot Direct)
PTX 117	Cannon JG, Long JP, Bhatnagar R. <i>Future directions in dopaminergic nervous system and dopaminergic agonists. J Med Chem</i> 1981; 24(10):1113-1118.	Admitted 12/19/2006 (Long Cross)
PTX 145	Cannon JG. <i>Structure-activity relationships of dopamine agonists. Annual Rev Pharmacol Toxicol</i> 1983; 23:103-129	Admitted 12/18/2006 (Long Cross)
PTX 156	Cannon JG, Lee T, Ilhan M, Koons J, Long JP. <i>6-Hydroxy-4-[2-(di-n-propylamino)ethyl]indole: synthesis and dopaminergic actions. J Med Chem</i> 1984; 27(3):386-389.	Admitted 12/20/2006 (Jenner Direct)
PTX 255	Rascol O, Brooks DJ, Korczyn AD, De Deyn, PP, Clarke, CE, Lang, AE. <i>A five-year study of the incidence of dyskinesia in patients with early Parkinson's Disease who were treated with ropinirole or levodopa. N. Engl J. Med.</i> 2000; 342:1484-91.	Admitted 12/19/2006 (Sudarsky Direct)
PTX 261	Mungersdorf M, Sommer U, Sommer M, Reichmann H. <i>High dose therapy with ropinirole in patients with Parkinson's Disease. J. of Neural Transmission</i> 2001; 108:1309-1317	Admitted 12/18/2006 (Tarsy Cross)
PTX 262	GlaxoSmithKline plc Annual Report for the year ended 31st December 2000	Stipulated
PTX 265	Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. <i>Practice parameter: Initiation of treatment for Parkinson's Disease: An evidence-based review: Report of the Quality Standards Subcommittee of the American Academy of Neurology.</i>	Admitted 12/19/2006 (Sudarsky Direct)
PTX 271	GlaxoSmithKline plc Annual Report for the year ended 31st December 2002	Stipulated
PTX 277	GlaxoSmithKline plc Annual Report for the year ended 31st December 2003	Stipulated
PTX 284	GlaxoSmithKline plc Annual Report for the year ended 31st December 2004	Stipulated
PTX 297	Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H, Hallett M, Miyasaki J, Stevens J, Weiner WJ. <i>Practice parameter: Treatment of Parkinson Disease with motor fluctuations and dyskinesia (an evidence-based review); Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology</i> 2006; 66:983-995.	Admitted 12/19/2006 (Sudarsy Direct)
PTX 304*	Expert Report of Christopher A. Velturo	Stipulated
PTX 311	Annual Report of GlaxoSmithKline plc for the year ended 31st December 2005	Stipulated

Exhibit Number	Description	Method of Admission
PTX 434	Curriculum Vitae, Paul A. Bartlett	Admitted 12/19/2006 (Bartlett Direct)
PTX 436	Curriculum Vitae, Lewis Sudarsky, M.D.	Admitted 12/19/2006 (Sudarsky Direct)
PTX 437	Curriculum Vitae, Christopher A. Velluro	Stipulated
PTX 438	Curriculum Vitae, Peter George Jenner	Admitted 12/19/2006 (Jenner Direct)
PTX 447	Long, J.P, et al. <i>Inhibitory receptors on the adrenergic nerve terminals</i> . Peripheral Dopaminergic Receptors. Pergamon, 1979:281-286.	Admitted 12/19/2006 (Long Cross)

List of Demonstratives Used During Trial for Identification Only		
Exhibit Number	Description	Date of Use
DDX 1	Defendant's Demonstrative Exhibit	12/18/2006 (Long Direct)
DDX 2	Defendant's Demonstrative Exhibit	12/18/2006 (Long Direct)
DDX 3	Defendant's Demonstrative Exhibit	12/18/2006 (Long Direct)
DDX 4	Defendant's Demonstrative Exhibit	12/18/2006 (Long Direct)
DDX 5	Defendant's Demonstrative Exhibit	12/18/2006 (Long Direct)
DDX 6	Defendant's Demonstrative Exhibit	12/18/2006 (Long Direct)
DDX 8	Defendant's Demonstrative Exhibit	12/18/2006 (Long Direct)
DDX 9	Defendant's Demonstrative Exhibit	12/18/2006 (Long Direct)
DDX 10	Defendant's Demonstrative Exhibit	12/18/2006 (Long Direct)
DDX 11	Defendant's Demonstrative Exhibit	12/18/2006 (Long Direct)
DDX 500	Defendant's Demonstrative Exhibit	12/18/2006 (Long Direct)
DDX 501	Defendant's Demonstrative Exhibit	12/18/2006 (Long Direct)
DDX 502	Defendant's Demonstrative Exhibit	12/18/2006 (Long Direct)
PDX 1	Plaintiff's Demonstrative Exhibit	12/19/2006 (Jenner Direct)
PDX 21	Plaintiff's Demonstrative Exhibit	12/19/2006 (Bartlett Direct)
PDX 22	Plaintiff's Demonstrative Exhibit	12/19/2006 (Bartlett Direct)
PDX 23	Plaintiff's Demonstrative Exhibit	12/19/2006 (Bartlett Direct)
PDX 24	Plaintiff's Demonstrative Exhibit	12/19/2006 (Bartlett Direct)
PDX 25	Plaintiff's Demonstrative Exhibit	12/19/2006 (Bartlett Direct)
PDX 26	Plaintiff's Demonstrative Exhibit	12/19/2006 (Bartlett Direct)
PDX 27	Plaintiff's Demonstrative Exhibit	12/19/2006 (Bartlett Direct)
PDX 28	Plaintiff's Demonstrative Exhibit	12/19/2006 (Bartlett Direct)
PDX 29	Plaintiff's Demonstrative Exhibit	12/19/2006 (Jenner Direct)

* Subject to any evidentiary objection to be raised in post-trial briefing.

CERTIFICATE OF SERVICE

I, Patricia Smink Rogowski, hereby certify that on February 7, 2007 LIST OF ADMITTED EXHIBITS was filed with the Court Clerk using CM/ECF which will send notification of such filing(s) to Josy W. Ingersoll.


I hereby further certify that on February 7, 2007, I have also served this document on the attorneys of record at the following addresses as indicated:

Via Hand Delivery

Josy W. Ingersoll, Esq.
Young Conaway Stargatt & Taylor LLP
1000 West Street, 17th Floor
Wilmington, DE 19801

Via Federal Express

Edward C. Donovan, Esq.
Andrew Kay, Esq.
Chanranjit Brahma, Esq.
Corey Manley, Esq.
Kirkland & Ellis LLP
655 Fifteenth Street, N.W., Suite 1200
Washington, DC 20005-5793
Main: (302) 576-8049
Fax: (302) 576-8158


Patricia Smink Rogowski (#2632)
CONNOLLY BOVE LODGE & HUTZ LLP
The Nemours Building
1007 N. Orange Street
Wilmington, DE 19801
(302) 658-9141
progowski@cblh.com